Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces...
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(...
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has co...
